Efficacy of lanreotide Autogel® administered every 4–8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial
T. Lucas, R. Astorga, , the Spanish–Portuguese Multicentre Autogel Study Group on AcromegalyVolume:
65
Year:
2006
Pages:
7
DOI:
10.1111/j.1365-2265.2006.02595.x
File:
PDF, 167 KB
2006